SCHERING OY – Trademark Portfolio

Entity Type: 99

SCHERING OY holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include MIRENA. The owner is based in FIN-20210 TURKU.

PANSIONTIE 47

FIN-20210 TURKU , FI

8 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

JADELLE
JADELLE
Cancelled 2004
Trademark
Serial #75707917
Registered 1999
JADELLE
JADELLE
Cancelled 1996
MIRENA
MIRENA
Registered 1995
BONEFOS
BONEFOS
Cancelled 1986

Trademark Classifications

SCHERING OY's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (8 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

10
Medical Apparatus (5 filings)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does SCHERING OY have?

SCHERING OY has 8 U.S. trademarks filed with the USPTO. Of these, 2 registered, 6 cancelled.

What trademark classes does SCHERING OY file in?

SCHERING OY files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are SCHERING OY's most well-known trademarks?

SCHERING OY's registered trademark portfolio includes well-known marks such as MIRENA. These are among 2 currently registered trademarks in the portfolio.

What is SCHERING OY's trademark registration success rate?

SCHERING OY has a 25% trademark registration rate, with 2 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.